⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for brca 1 gene mutation

Every month we try and update this database with for brca 1 gene mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer PatientsNCT04556292
Breast Cancer M...
BRCA 1 Gene Mut...
BRCA 2 Gene Mut...
SC10914
18 Years - Jiangxi Qingfeng Pharmaceutical Co. Ltd.
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)NCT01945775
Breast Neoplasm...
BRCA 1 Gene Mut...
BRCA 2 Gene Mut...
talazoparib
Physician's-Cho...
18 Years - Pfizer
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.NCT02000622
Breast Cancer M...
BRCA 1 Gene Mut...
BRCA 2 Gene Mut...
Olaparib
Physician's cho...
18 Years - 99 YearsAstraZeneca
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)NCT01945775
Breast Neoplasm...
BRCA 1 Gene Mut...
BRCA 2 Gene Mut...
talazoparib
Physician's-Cho...
18 Years - Pfizer
A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer PatientsNCT04556292
Breast Cancer M...
BRCA 1 Gene Mut...
BRCA 2 Gene Mut...
SC10914
18 Years - Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.NCT02000622
Breast Cancer M...
BRCA 1 Gene Mut...
BRCA 2 Gene Mut...
Olaparib
Physician's cho...
18 Years - 99 YearsAstraZeneca
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.NCT02000622
Breast Cancer M...
BRCA 1 Gene Mut...
BRCA 2 Gene Mut...
Olaparib
Physician's cho...
18 Years - 99 YearsAstraZeneca
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)NCT02034916
Breast Neoplasm...
BRCA 1 Gene Mut...
BRCA 2 Gene Mut...
talazoparib
18 Years - Pfizer
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)NCT02034916
Breast Neoplasm...
BRCA 1 Gene Mut...
BRCA 2 Gene Mut...
talazoparib
18 Years - Pfizer
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: